Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Turning green: the impact of changing to more eco-friendly respiratory healthcare. A carbon and cost analysis of Dutch prescription data

View ORCID ProfileHans C Ossebaard, View ORCID ProfilePieter ten Have, Peter Th. W. van Hal, View ORCID ProfileIris Wichers, Johan Kooistra, View ORCID ProfilePaul Hagedoorn, View ORCID ProfileEvelyn Brakema, View ORCID ProfileNiels Chavannes, View ORCID ProfilePauline de Heer
doi: https://doi.org/10.1101/2021.11.20.21266571
Hans C Ossebaard
1National Health Care Institute, P.O. Box 320, 1110 AH, Diemen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hans C Ossebaard
  • For correspondence: hossebaard@zinl.nl
Pieter ten Have
2Dutch National Health Care Institute, Diemen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pieter ten Have
Peter Th. W. van Hal
3Dept. of Respiratory Medicine, Van Weel - Bethesda Hospital, Dirksland, The Netherlands
2Dutch National Health Care Institute, Diemen, The Netherlands
Roles: Medical Advisor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iris Wichers
4Dutch College of General Practitioners, Utrecht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Iris Wichers
Johan Kooistra
5BENU Pharmacies, Maarssen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Hagedoorn
6Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul Hagedoorn
Evelyn Brakema
7Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Evelyn Brakema
Niels Chavannes
7Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Niels Chavannes
Pauline de Heer
8National Health Care Institute, Diemen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pauline de Heer
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives Dry powder inhalers (DPIs) and soft mist inhalers have a substantially lower global warming potential than pressurized metered-dose inhalers (pMDIs). To help mitigate climate change, we assessed the potential emission reduction in CO2-equivalents when replacing pMDIs by non-propellant inhalers in Dutch respiratory healthcare, and estimated the associated costs.

Design We performed a four-step analysis based on data from two national databases of two independent governmental bodies (the Dutch National Healthcare Institute and the Dutch Healthcare Authority). First, we calculated the number of patients with chronic obstructive pulmonary disease and asthma that were using inhalation medication (2020). Second, we calculated the number and total of daily defined doses of pMDIs and non-propellant inhalers (NPIs) that include dry powder inhalers and soft mist inhalers, as well as the number of spacers per patient dispensed by non-hospital based pharmacies in 2020. Third, we estimated the potential reduction in greenhouse gas emission if 70% of patients would switch from using pMDIs to using NPIs as eco-friendly alternatives. Fourth, we performed a budget impact analysis.

Results In 2020, 1.4 million patients used inhalers for COPD or asthma treatment. A total of 460 million defined daily doses (DDDs) from inhalers were dispensed, of which – after the exclusion of nebulizers – 50.4% through pMDIs. We estimated that this usage could be reduced by 70% which would lead to an annual reduction in greenhouse gas emission of 77 - 84 million kg. CO2eq. saving at best EUR 49.8 million per year.

Conclusions In the Netherlands, substitution of pMDIs to NPIs for eligible patients is theoretically safe and in accordance with medical guidelines, while reducing greenhouse gas emission by 80 million kg. CO2eq. on average and saving at best EUR 49.8 million per year. This study confirms the potential climate and economic benefit of delivering a more eco-friendly respiratory care.

Strengths and limitations of this study

  • Given availability and reliability of the data, the present analysis can easily be replicated elsewhere which allows for international comparison and aggregation.

  • Implementation challenges remain underexposed.

Competing Interest Statement

PtH, PvH, IW, PdH, EB, NC, PdH and HCO, report no competing interests. JK reports personal fees from BENU Pharmacists, BENU Nederland B.V. / Brocacef Groep N.V.

Funding Statement

This study was funded by the Dutch National Health Care Institute

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Data sources are openly available at - GIP database (2021). Genees- en hulpmiddelen Informatie Project | Medicines and medical devices Information Project. Available: https://www.gipdatabank.nl/ - DIS database (2021). DBC Informatie Systeem | Diagnosis-Treatment Combination Information system. Available: https://www.opendisdata.nl/

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Due to an updated pharmaceutical reference-table the data-analist in our team has generated new figures over 2020 that suggest a higher environmental impact and an increasd budget impact of theoretically replacing pMD-inhalers in Dutch respiratory care. We have adapted the figure and tables in our paper accordingly and conclude that the internal argumentation is not affected by these revised outcomes. We have changed 'MDIs' for 'pMDI' because this is more accurate in practice. We have introduced 'non-propellant inhalers' (NPIs), a class of inhalers consisting of both dry powder inhalers (DPIs) and soft mist inhalers, in order to include the latter in the calculation. Corrected order of authors. We have adapted the language.

Data Availability

All data produced in the present work are contained in the manuscript or in its attachments

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted November 28, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Turning green: the impact of changing to more eco-friendly respiratory healthcare. A carbon and cost analysis of Dutch prescription data
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Turning green: the impact of changing to more eco-friendly respiratory healthcare. A carbon and cost analysis of Dutch prescription data
Hans C Ossebaard, Pieter ten Have, Peter Th. W. van Hal, Iris Wichers, Johan Kooistra, Paul Hagedoorn, Evelyn Brakema, Niels Chavannes, Pauline de Heer
medRxiv 2021.11.20.21266571; doi: https://doi.org/10.1101/2021.11.20.21266571
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Turning green: the impact of changing to more eco-friendly respiratory healthcare. A carbon and cost analysis of Dutch prescription data
Hans C Ossebaard, Pieter ten Have, Peter Th. W. van Hal, Iris Wichers, Johan Kooistra, Paul Hagedoorn, Evelyn Brakema, Niels Chavannes, Pauline de Heer
medRxiv 2021.11.20.21266571; doi: https://doi.org/10.1101/2021.11.20.21266571

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Respiratory Medicine
Subject Areas
All Articles
  • Addiction Medicine (164)
  • Allergy and Immunology (417)
  • Anesthesia (93)
  • Cardiovascular Medicine (867)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (398)
  • Epidemiology (8597)
  • Forensic Medicine (4)
  • Gastroenterology (391)
  • Genetic and Genomic Medicine (1775)
  • Geriatric Medicine (170)
  • Health Economics (376)
  • Health Informatics (1252)
  • Health Policy (625)
  • Health Systems and Quality Improvement (472)
  • Hematology (198)
  • HIV/AIDS (380)
  • Infectious Diseases (except HIV/AIDS) (10355)
  • Intensive Care and Critical Care Medicine (554)
  • Medical Education (193)
  • Medical Ethics (51)
  • Nephrology (214)
  • Neurology (1692)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (330)
  • Occupational and Environmental Health (451)
  • Oncology (934)
  • Ophthalmology (265)
  • Orthopedics (104)
  • Otolaryngology (172)
  • Pain Medicine (115)
  • Palliative Medicine (40)
  • Pathology (256)
  • Pediatrics (541)
  • Pharmacology and Therapeutics (257)
  • Primary Care Research (210)
  • Psychiatry and Clinical Psychology (1788)
  • Public and Global Health (3877)
  • Radiology and Imaging (629)
  • Rehabilitation Medicine and Physical Therapy (324)
  • Respiratory Medicine (525)
  • Rheumatology (208)
  • Sexual and Reproductive Health (171)
  • Sports Medicine (159)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)